Articles tagged with Chemotherapy
Research on carboplatin therapy in rats suggests that chemotherapy can affect dopamine and serotonin levels, leading to cognitive issues. The study provides new insights into the development of chemo brain, a condition affecting up to one-third of chemotherapy patients.
Researchers have found that a combination of vitamin A and chemotherapy can reduce cancer cell proliferation and invasion in pancreatic cancer. The approach targets both cancer cells and surrounding stromal cells, blocking multiple cell signalling pathways used by cancer cells to become aggressive.
Mayo Clinic researchers found that a combination of chemotherapy, radiation, and surgery can significantly improve survival rates for pancreatic cancer patients. Patients who received chemotherapy and/or radiation before surgery had better long-term outcomes than those who did not, with median survival times approaching four years.
Researchers discovered that immune T cells can overcome chemotherapy resistance in ovarian cancer by outsmarting fibroblasts. By boosting these immune cells, the tumor cells begin to die off, suggesting a new approach to treating ovarian cancer.
University at Buffalo researchers have created a method to strip away excess surfactants from common injectable drugs, potentially making them safer and more effective for millions. The breakthrough removes potentially harmful additives, improving the formulation of anti-cancer medicine, testosterone, and other drugs.
A research team identified low expression of methylation-controlled J protein (MCJ) as a marker of poor response to chemotherapy in triple-negative breast cancer patients. They found that MCJ-expressing tumors had reduced relapse-free survival and that mice deficient in MCJ had larger tumors and increased chemoresistance.
A study published in Brain Connectivity suggests that pediatric leukemia survivors may experience cognitive impairment due to chemotherapy-induced brain damage. The research used diffusion tensor imaging to analyze the white matter connectome of ALL survivors and healthy young people, revealing significantly lower connectivity and grea...
Researchers at the University of Zurich have discovered a new way to kill off resistant leukemia cells via necroptosis, a cell death program that can bypass traditional apoptosis. SMAC mimetics, which activate necroptosis, showed promise in killing leukemia cells in 33% of patient samples tested.
Cisplatin kills rapidly dividing cancer cells but also causes permanent hearing loss due to damage to sensory hair cells in the inner ear. Individuals with Cockayne syndrome, a genetic disorder affecting DNA repair, are more susceptible to this side effect.
Women with early-stage breast cancer who used dietary supplements and complementary medicine were less likely to start chemotherapy than nonusers, according to a new study. CAM use was associated with lower chemotherapy initiation rates among those for whom treatment was indicated.
Women with early-stage breast cancer who used dietary supplements and complementary therapies were less likely to start chemotherapy. Dietary supplement usage was associated with a lower likelihood of initiating chemotherapy, while mind-body practices showed no relation.
Researchers used pharmacologic modeling and simulation to calculate optimal drug doses for a clinical trial of ependymoma patients. The approach led to the development of a successful phase I clinical trial with a recommended dose of 500mg/m2 body surface area administered weekly.
A randomized study found that chemoradiotherapy did not improve overall survival compared to chemotherapy in patients with locally advanced pancreatic cancer, contradicting prior expectations. The study also showed no significant difference between gemcitabine and gemcitabine plus erlotinib treatments.
A new study suggests that cognitive-behavioral therapy can help prevent long-term memory issues caused by chemotherapy. The therapy, called Memory and Attention Adaptation Training (MAAT), was developed to increase awareness of situations where memory problems arise and develop skills to compensate for memory dysfunction.
A large study of 2,437 patients with stage II testicular seminoma found that radiation therapy was associated with better outcomes compared to chemotherapy, particularly in stage IIa disease. The study's findings support the recommendation for radiotherapy as the preferred treatment option for early-stage II testicular cancer.
The International Association for the Study of Lung Cancer (IASLC) highlights significant progress in lung cancer prevention, diagnosis, staging, and treatment in 2015. The organization introduces a comprehensive educational resource covering topics such as tobacco control, early detection, and immunotherapy.
Breast cancer survivors undergoing anthracycline-based chemotherapy did not experience greater risk of lasting cognitive decline, according to a recent study. Neuropsychological tests revealed comparable cognitive function between groups up to seven years after treatment.
A phase III trial found that patients taking nivolumab were more than twice as likely to be alive after one year compared to those treated with chemotherapy. Median survival for nivolumab was 7.5 months, significantly longer than 5.1 months for chemotherapy.
A 20-month-old girl's tumor regression shows promising evidence of the potential for LOXO-101 to provide significant benefit for pediatric patients with NTRK gene fusions. The patient achieved a 90% reduction in tumor size after receiving an experimental treatment.
Researchers create micro-sized gas bubbles coated with cancer drug particles that can be directed to a specific tumour using magnets and ultrasound. This innovative technique aims to overcome limitations of chemotherapy by delivering drugs directly to the core of the tumour.
Researchers at Beth Israel Deaconess Medical Center have found a way to attack a process that tumor cells use to escape the effects of standard cancer drugs. The discovery highlights how targeting specific metabolic requirements of cancer cells can prove effective in their selective eradication.
Patients with EGFR expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy. The addition of necitumumab improves overall survival and progression-free survival by 21% and 16%, respectively, in patients whose tumours express the EGFR protein.
Researchers at the University of Missouri have discovered a compound that not only lowers cholesterol but also kills prostate cancer cells. The study found that the compound, initially developed as a cholesterol-fighting molecule, reduced prostate cancer cell growth and caused cancer cell death in human and mouse models.
Researchers at Children's Hospital Los Angeles found that targeting survivin enhances chemotherapy effectiveness in retinoblastoma cells and mouse models. The combination of a survivin inhibitor with chemotherapy agents increased Rb cell death, demonstrating a therapeutic advantage.
Patients with grade 2 gliomas treated with radiation therapy plus chemotherapy had a better overall survival of 13.3 years compared to 7.8 years without chemotherapy. The study also found that patients with IDH1 mutation had significantly better overall survival regardless of treatment.
Researchers have developed an implantable device that delivers chemotherapy drugs directly to pancreatic tumors, showing promising results in slowing disease progression and shrinking tumors. The device uses a flexible film that conforms to the tumor shape and releases drugs locally, minimizing side effects and improving treatment outc...
A phase Ib trial demonstrated that combining immunotherapy with live bacterium CRS-207 and chemotherapy resulted in a 94% disease control rate and 59% response rate in patients with malignant pleural mesothelioma. The therapy also showed good immune activation and synergistic efficacy with chemotherapy.
A new hybrid drug combines parts of chloroquine and a chemoreversal agent to counteract malaria resistance. The dual-acting mechanism kills the parasite by concentrating the drug in its stomach.
Researchers at CNIO have identified a protein, CDC25A, as a determinant of chemotherapy resistance in cancer cells. They used CRISPR genome editing technology to test various mutations and found that cells with this mutation were resistant to treatment.
Patients with grade 2 glioma who received radiation therapy plus PCV chemotherapy experienced longer progression-free and overall survival times compared to those who received radiation therapy alone. The treatment combination improved survival rates by up to 10 years.
A phase 1b clinical trial shows that an experimental therapy can control pancreatic cancer tumors well enough to make patients eligible for surgery. The treatment, PF-04136309, was found to be safe and effective when combined with chemotherapy.
A new study reveals that despite the availability of lung cancer tests and treatment to 70% of the world's population, large discrepancies exist in patient access. The study found that many poorer countries lack access to essential tests and treatments due to high costs and low HDI scores.
Researchers have discovered that high doses of cyclophosphamide can selectively kill reactive immune cells, reducing the severity of graft-versus-host disease (GVHD) in patients. This breakthrough has paved the way for the use of mismatched donors in stem cell transplantation, improving access to treatment for many patients.
Scientists developed triple-stage nanoparticles that improve tumor penetration and release cisplatin in acidic conditions, enhancing its efficacy while reducing toxic side effects. The delivery system demonstrated significant improvements in anti-tumor activity against various cancer models.
Researchers developed a new technique using nanoparticles that deliver therapeutic payloads and glow green when cancer cells begin dying. This allows for early detection of treatment effectiveness, potentially improving patient outcomes and quality of life.
A study published in Antimicrobial Agents and Chemotherapy found that patients with S. aureus skin and soft tissue infections took only 57% of their prescribed antibiotic doses after leaving the hospital. This led to nearly half of them getting a new infection or requiring additional treatment.
A study published in The Lancet Oncology found that most female childhood cancer survivors can conceive, but male survivors are less likely to father a child due to chemotherapy exposure. Female survivors treated with certain drugs like ifosfamide and cisplatin may face challenges conceiving, particularly after age 30.
Researchers at Queensland University of Technology have developed a new 3D printable material that mimics human tissue, allowing for the creation of tumor microenvironments to test anti-cancer drugs. This breakthrough enables rapid, personalized cancer treatment targeting tumors, not entire bodies.
African American patients are less likely to receive a common genomic test that predicts the seriousness of early-stage breast cancer. The study found higher scores among African Americans, indicating an increased likelihood of aggressive tumor biology benefiting from chemotherapy.
Researchers have synthesized novel selenohydantoins with promising anticancer and antioxidant activity, leveraging the potential of selenium to slow down oxidation processes. The study's findings highlight the importance of structural modification in influencing biological activity.
A new study found that a 21-gene test can identify patients with early breast cancer who can be spared chemotherapy and still survive five years after diagnosis. The trial showed a 94% disease-free survival rate among low-risk patients treated with hormone therapy alone.
A new study from the University of Texas M. D. Anderson Cancer Center found that neurofeedback significantly reduces chronic pain and improves quality of life in cancer patients with chemotherapy-induced neuropathy. The treatment, which uses electroencephalogram biofeedback to modify brain activity, showed a 73% improvement rate in pai...
A clinical trial found that approximately a quarter of women with HER2 positive breast cancer who received combination treatment experienced significant tumor shrinkage or disappearance within 11 days. This discovery offers the possibility of tailoring treatment for each woman, potentially reducing the need for chemotherapy.
A new study found that low expression of SMARCA4/BRG1 gene in lung tumors may indicate patients who will benefit from certain chemotherapy regimens. The findings suggest an alternative therapy for these patients to spare them from cisplatin's side effects and allow them to try a different treatment sooner.
Researchers at Rice University have developed a new method for synthesizing the potent anti-cancer agent trioxacarcin, which damages DNA and disrupts cancer cell replication. This breakthrough allows for more efficient production of these valuable molecules, enabling their study as potential new medications.
Researchers found that dose-dense adjuvant chemotherapy significantly improved overall survival after ten years by nearly a third compared to standard interval regimens. Dose-dense chemotherapy was not associated with an increased risk of treatment-induced amenorrhea, and it seemed effective irrespective of hormone receptor status.
Nanoparticulate drug carriers show promise in targeted cancer therapy, increasing therapeutic concentrations at tumor sites while minimizing harm to healthy tissues. This approach has the potential to improve treatment efficacy and reduce systemic toxicity.
Researchers identified 12 classes of drugs and 4 main mechanisms that can cause small arteries to constrict in response to cold, limiting blood supply. A recent study published in British Journal of Clinical Pharmacology highlights the need for further investigation into this condition.
Researchers at St. Joseph's Hospital and Medical Center found that a standard front-line treatment for advanced ovarian cancer should involve every three week chemotherapy with carboplatin, paclitaxel plus bevacizumab, or weekly dose intense paclitaxel without bevacizumab
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Using laser probe, neurosurgeons deliver chemotherapy drugs to patients with glioblastoma after opening the blood-brain barrier. The technology allows for longer treatment windows and potentially limits harmful effects of chemotherapy.
Researchers develop adaptive therapy that adjusts drug dose based on tumor response, controlling growth and allowing 60-80% of mice to be weaned off the drug. The treatment approach stabilizes tumors by maintaining a small population of drug-sensitive cells to suppress resistant cell growth.
Researchers at MDI Biological Laboratory have discovered two drugs that could reverse peripheral nerve damage caused by chemotherapy, with applications also for diabetes and traumatic injuries. The drugs reduce MMP-13 activity, preventing degeneration of axons and restoring touch response in zebrafish.
Researchers from Case Western Reserve University have developed a new image analytics test that can reliably distinguish between patients who need only hormonal treatment and those who also need chemotherapy. The test uses MRI data to identify molecular changes in tissues, which can be analyzed quickly and cost-effectively.
A large-scale analysis of patient records found that chemotherapy before radiation therapy did not improve overall survival rates for head and neck cancer patients. Patients who received concurrent chemotherapy and radiation had slightly longer median overall survival times compared to those receiving chemotherapy alone.
A new study suggests that patients with resectable pancreatic cancer should receive at least 6 months of adjuvant chemotherapy to reduce distant disease recurrences and improve overall survival. Chemotherapy, but not chemoradiotherapy, significantly reduces the incidence of distant recurrence.
A recent clinical study found that ONC201 caused cell death in various tumor types, even when the p53 protein was mutated or deleted. The drug has shown promise in treating hematological malignancies, including leukemia and lymphoma patients, with clinical trials recently initiated.
Researchers from Massachusetts General Hospital report that inducing cytotoxic T cell infiltration into lung tumors can make them sensitive to checkpoint blockade. Combining chemotherapy with immune checkpoint therapies achieves long-lasting control of tumor growth in animal models, expanding the potential for effective treatment.
Researchers found that pediatric ALL patients treated with chemotherapy alone remain at risk for attention and learning problems, even after treatment ends. The study, published in the Journal of Clinical Oncology, suggests that early intervention is crucial to prevent academic difficulties.
A new study from Children's Hospital Los Angeles found that leukemia therapy leads to a significant drop in bone mineral density during the first month of treatment, affecting the lower spine and legs. This earlier onset than previously thought highlights the need for new approaches to mitigate bone toxicity in cancer patients.